New-look Novo is digging deeper into its metabolic roots with three new obesity programs purchased from New York biotech Kallyope.
The three new programs are not incretins, the class of gut hormones that includes GLP-1s like Novo’s semaglutide. Instead, one is a “potential first-in-class peptide,” another is a “follow-on small molecule” for a novel target and the third is a “small molecule receptor agonist,” Jacob Petersen, Novo’s head of global research, wrote in a LinkedIn post today.
“The lead peptide-based candidate, K-554, is IND-ready,” Petersen wrote.
Kallyope shared some details on K-554 in January when outlining the company’s strategic priorities for the year. At the time, the biotech said the drug candidate is a “novel, once weekly, non-incretin approach to regulating food intake” that leverages a different realm of biology than GLP-1s.
Kallyope said it was working to start phase 1 testing of K-554, with data expected in the second half of 2026.
The drug is not currently listed on Kallyope’s pipeline, and no clinical trials of the asset being run by the company are listed on the federal trial database.
“As we work to address the diverse needs of people living with obesity, we continue to build a broad and deep pipeline spanning a variety of treatment approaches, with multiple candidates entering clinical development this year,” Petersen wrote. “This agreement builds on Novo’s long tradition of pursuing new possibilities to improve health.”
Though Novo and Kallyope have teamed up in the past, this deal is new, a Novo spokesperson confirmed to Fierce. The company is not sharing further details on financial terms or drug targets for the time being.
“By acquiring these programs, we add promising externally grown science to our obesity pipeline and build on our ambition to look beyond our own walls to identify opportunities that can strengthen and differentiate our pipeline,” Tamara Darrow, Ph.D., Novo’s head of global business development, said in her own LinkedIn post.
The deal comes just a day after Novo announced a $1.4 billion biobucks pact with Orbis Medicines to develop macrocycle drugs aimed at “high-value” cardiometabolic targets.
The three obesity newcomers arrive at Novo during a time of renewal, with the Danish drug giant recently announcing a brand refresh that dropped the “Nordisk” from the company’s everyday moniker. Novo has been racing to keep up with Lilly in the obesity field, and CEO Mike Doustdar recently told Fierce that obesity and diabetes remain “very core to what we do.”
Novo’s pipeline recently took a blockbuster-sized hit when the pharma gave up on two more phase 3 trials of ziltivekimab, an interleukin-6 ligand that was being tested for heart failure. That followed the drug’s earlier phase 3 failure in atherosclerotic cardiovascular disease, chronic kidney disease and inflammation.
Analysts had previously projected peak sales of around $3 billion for ziltivekimab, heralding the drug as a chance for Novo to expand its cardiovascular presence beyond obesity and diabetes.
Facts Only
* Novo purchased three obesity programs from Kallyope.
* The programs consist of one potential first-in-class peptide, one follow-on small molecule for a novel target, and one small molecule receptor agonist.
* These candidates are non-incretins and differ biologically from GLP-1s.
* The peptide-based candidate, K-554, is IND-ready.
* K-554 is designed for once-weekly administration to regulate food intake.
* Phase 1 testing data for K-554 is expected in the second half of 2026.
* Novo recently entered a $1.4 billion agreement with Orbis Medicines for cardiometabolic macrocycle drugs.
* Novo dropped "Nordisk" from its everyday brand name.
* Novo discontinued two phase 3 trials of ziltivekimab for heart failure.
* Ziltivekimab previously failed phase 3 trials for atherosclerotic cardiovascular disease, chronic kidney disease, and inflammation.
* Financial terms and specific drug targets for the Kallyope deal were not disclosed.
Executive Summary
Novo is diversifying its metabolic pipeline by acquiring three non-incretin obesity programs from Kallyope. These assets—comprising a peptide (K-554) and two small molecules—aim to regulate food intake through biological pathways distinct from the GLP-1 hormones used in semaglutide. K-554 is currently IND-ready, with initial clinical data anticipated by late 2026. This strategic pivot toward a "broad and deep pipeline" occurs alongside a $1.4 billion partnership with Orbis Medicines targeting cardiometabolic diseases.
This aggressive expansion into new obesity modalities comes at a time of corporate rebranding and significant clinical setbacks. Novo recently abandoned multiple phase 3 trials for ziltivekimab, a drug previously projected to generate $3 billion in peak sales. While the company continues to prioritize obesity and diabetes as core business pillars to maintain competitiveness against Eli Lilly, the shift toward non-incretin targets suggests an effort to hedge against the limitations of current gut-hormone therapies and recover lost ground in the cardiovascular space.
Full Take
The strongest version of this narrative is a pharmaceutical giant proactively diversifying its scientific risk. By moving beyond the GLP-1 "gold rush," Novo is attempting to ensure long-term dominance in metabolic health by owning multiple biological pathways to weight loss.
The narrative relies heavily on executive optimism to counterbalance concrete clinical failure. The juxtaposition of the ziltivekimab collapse—a multi-billion dollar loss in projected value—with the announcement of "promising externally grown science" serves to pivot the conversation from a realized loss to a potential future gain. While the excitement surrounding "first-in-class" peptides is high, the assets remain pre-clinical or early-stage, creating a temporal gap between the current corporate crisis and the 2026 data expectations.
Patterns detected: none
The driving paradigm is the "Innovation Hedge." In high-stakes biotech, the fear of a single-mechanism plateau (where GLP-1s reach a ceiling of efficacy or safety) drives the acquisition of any viable alternative pathway. This echoes the historical pattern of "pipeline filling" following a blockbuster failure, where the goal is to signal stability to shareholders.
The second-order consequence is the consolidation of metabolic control. As a few firms acquire the majority of non-incretin research, the path to alternative obesity treatments becomes centralized, potentially limiting the diversity of available therapies for patients who do not respond to current hormones.
Bridge Questions:
1. How does the lack of disclosed drug targets affect the ability to independently verify the "novelty" of these programs?
2. To what extent is the "brand refresh" a psychological tool to distance the company from recent clinical failures?
Counterstrike Scan: A coordinated campaign would use "science-washing" to mask financial instability by flooding the news cycle with technical jargon about "novel targets" to distract from a failing primary asset. The actual content here is standard corporate reporting and does not match the intensity of a coordinated influence campaign.